Development and validation by statistical treatment of stability indicating RP-HPLC method for quantification of Orlistat in Orlistat-loaded solid dispersion
Open Access
- 10 February 2021
- journal article
- research article
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 7 (1) , 1-13
Abstract
Background: Most of the analytical methods reported for the estimation of Orlistat were complex, expensive, and deficient in reproducibility with no or very less informative regarding various statistical methods and equations used for the validation purpose. This study provides a fast, accurate, descriptive, and precise isocratic reversed phase high-performance liquid chromatographic (HPLC) method using Waters Spherisorb 5 μm Octadecyl-silica-2 (250 × 4.6 mm) column, for the estimation of Orlistat in bulk drug and pharmaceutical formulations with minimized drug extraction steps. The drug was detected in an analytical column with mobile phase comprising a mixture of methanol, acetonitrile, and 2% phosphoric acid in the ratio of 85:14:1 v/v/v at flow rate of 1 ml/min with elution monitoring at 215.0 nm. Results: The retention time for Orlistat was found to be 5.9 min with sharp and proper peak. The linearity was covered over the concentration range of 1.00–10.00 μg/ml (r2 = 0.9997) with a limit of detection and limit of quantitation 0.06 and 0.2 μg/ml, respectively. The developed analytical technique was found to be validated for all the parameters within the acceptance criteria of ICH guidelines. The mean ± standard deviation (SD) recoveries of Orlistat were 99.87 ± 0.45. Conclusion: The optimized method was well precise, accurate, sensitive, stability indicating, and tested with all statistical parameters. Thus, the method can be conveniently used in quality control and routine analysis of Orlistat containing solid dispersions and other formulations. The main advantage of the developed method was its high specificity for the estimation of Orlistat in presence of various degradation products resulting from stress conditions and formulation excipients.Keywords
This publication has 20 references indexed in Scilit:
- Nanoemulsified orlistat-embedded multi-unit pellet system (MUPS) with improved dissolution and pancreatic lipase inhibitionPharmaceutical Development and Technology, 2012
- Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2010
- Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibitionInternational Journal of Pharmaceutics, 2010
- Bioanalytical method validation: An updated reviewPharmaceutical Methods, 2010
- Osmotic flow through asymmetric membrane: A means for controlled delivery of drugs with varying solubilityAAPS PharmSciTech, 2006
- A stability-indicating high performance liquid chromatographic assay for the determination of orlistat in capsulesJournal of Chromatography A, 2006
- Effect of Orlistat on Weight and Body Composition in Obese AdolescentsJAMA, 2005
- Cost-effectiveness of orlistat for the treatment of overweight and obese patients in IrelandInternational Journal of Obesity, 2005
- Influence of orlistat on bone turnover and body compositionInternational Journal of Obesity, 2001
- One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitorInternational Journal of Obesity, 2000